Nektar(US:NKTR) Globenewswire·2025-12-30 17:40Core Viewpoint - Pomerantz LLP is investigating claims on behalf of investors of Nektar Therapeutics regarding potential securities fraud or unlawful business practices by the company and its officers or directors [1]. Group 1: Company Performance - On December 16, 2025, Nektar announced topline results from the Phase 2b REZOLVE-AA trial of its investigational drug rezpegaldesleukin, which failed to reach statistical significance due to the inclusion of four ineligible patients [3]. - Following the announcement of the trial results, Nektar's stock price dropped by $4.14 per share, or 7.77%, closing at $49.16 per share on the same day [4]. Group 2: Legal Investigation - Pomerantz LLP, a firm known for its work in corporate and securities class litigation, is leading the investigation into Nektar's business practices and potential fraud [5].